Pricing Log in Create free account

Keros Therapeutics, Inc. (KROS) vs Lexeo Therapeutics, Inc. (LXEO)

Keros Therapeutics, Inc. and Lexeo Therapeutics, Inc. are both Biotechnology companies. Keros Therapeutics, Inc. and Lexeo Therapeutics, Inc. are of similar size ($226.6M and $220.1M). Across the 11 metrics below, Keros Therapeutics, Inc. leads on 10 and Lexeo Therapeutics, Inc. on 1.

Valuation

Metric KROS LXEO Biotechnology median
P/E n/m n/m 8.50
P/S 6.37 n/m 9.71
P/B 0.81 0.96 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.46 n/m 0.64
EV/Sales (1.39) n/m 9.21
Earnings yield (34.64%) (43.56%) (33.15%)
Free cash flow yield (22.93%) (39.24%) (25.50%)

Profitability

Metric KROS LXEO Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (17.16%) (46.76%) (56.36%)
Return on assets (15.92%) (40.50%) (48.04%)
Return on invested capital (1,345.30%) (253.48%) 0.00%

Growth

Metric KROS LXEO Biotechnology median
Revenue growth (TTM) (84.55%) — 6.02%
EPS growth (last fiscal year) 146.00% 39.81% 30.26%
Revenue growth, 5-year CAGR 89.45% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KROS LXEO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 21.96 13.89 4.72
Net debt to EBITDA (4.16) 1.67 0.96

Dividend

Metric KROS LXEO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KROS LXEO Biotechnology median
Market cap 220.08m 226.56m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack